ReGen Therapeutics - Results of Study

RNS Number:1040R
ReGen Therapeutics PLC
31 March 2008

31 March 2008 embargoed for 9am

Research Update

In-vivo study shows ReGen's ColostrininTM to be non-allergenic and able to
prevent allergic inflammation

ReGen Therapeutics Plc ('ReGen') is pleased to announce a report of a study
conducted by Dr Istvan Boldogh* of the University of Texas Medical Branch was
published on the 27 March on line in the International Archives of Allergy and
Immunology. This study shows that ColostrininTM , ReGen's nutraceutical product,
being marketed by Metagenics Inc., California for the 'support of healthy brain
ageing and cognition', is not only non-allergenic, but prevents allergic
inflammation due to common indoor and outdoor allergens.

Currently Metagenics and or its subsidiaries are selling ColostrininTM in
Australasia since July 2007 and North America since October 2007. Headquartered
in San Clemente, California, Metagenics is a leading developer, manufacturer and
marketer of nutraceuticals, dedicated to researching and evaluating the effects
of natural ingredients on genetic expression and protein activity. Additionally,
on 25 March 2008 ReGen announced its first approval to launch in the European
Union in Cyprus through Golgi Pharmaceuticals Ltd its distributor for that
market.

Highlights of the study are as follows:

• The objective of the study was to investigate potential allergic
responses to ColostrininTM and its impact on allergic sensitisation and
inflammation caused by common allergens to underpin its safe use as a human
nutraceutical . A spray-dried whole Colostrum product which is commercially
available as a nutraceutical was used as a control
• The study used a well characterised mouse model of allergic airway
inflammation
• ColostrininTM (given orally, intranasally or intraperitoneally)
significantly decreased IgE/IgG1 production, airway eosinophilia, mucin
production and hypersensitivity induced by allergenic extracts from ragweed
pollen and house dust mites
• In contrast, Colostrum, from which ColostrininTM is derived, induced
positive inflammatory responses

Commenting on these findings Dr. Marian Kruzel (a co-author of the publication
and a scientific advisor to ReGen) said: ' These findings are entirely
consistent with Colostrinin'sTM safety profile and use to support healthy
cognition through significant reduction of reactive oxygen species (ROS) build
up.'

Percy Lomax, Chairman and Chief Executive Officer added: 'The data shows that
ColostrininTM may be used in humans without concern about experiencing an
allergic reaction. This is in contrast to other less refined dairy-derived
products, in particular whole colostrum, which is a significant US dietary
product. We believe these findings will give impetus to the marketing of
ColostrininTM.

Notes:

*To read the full report please go to http://www.karger.com and search for the
International Archives of Allergy and Immunology 2008;146:298-306. This study
was conducted by Dr Istvan Boldogh at the University of Texas Medical Branch,
Galveston, Texas, USA. ReGen has a sponsored research agreement with the
University of Texas Medical Branch, Galveston, Texas, USA.

A complete copy of the paper will be added to the ReGen website
(www.regentherapeutics.com) soon.

For further information, please contact:

Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920

Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396

This information is provided by RNS
The company news service from the London Stock Exchange

END
MSCILFETVLITFIT